Materialise Reports Q3 2026 Results with Strong Medical Segment Growth and Increased Free Cash Flow
Materialise NV (MTLS) reported third-quarter revenue of €67.7 million, a 2% year-over-year increase that reaches nearly 5% growth when excluding recent divestitures. The company saw significant strength in its medical segment, which grew by approximately 10%, and its series production division, which surged over 30% due to demand from the aerospace, semiconductor, and defense sectors. Despite these gains, the software and manufacturing segments faced headwinds, with revenue declining by 4% and 6% respectively as customer spending became more cautious. However, profitability metrics remained stable with a gross margin of 57.7%, and free cash flow for the first nine months of 2026 reached €22.8 million, more than doubling from the previous year. Management reconfirmed its full-year 2026 guidance for revenue (€273M–€283M) and adjusted EBIT (€12M–€14M). The company continues to prioritize cash generation and shareholder returns, having invested €7.5 million in share buybacks through the first three quarters of the year.
Tickers: $MTLS
Topics: Gross Margin Net Profit Revenue Growth Segment Performance Share Buyback